Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol - Test2 - elhamkhani - TriplyDB

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

http://www.wikidata.org/entity/Q28255410

about

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 CETP Inhibition: Past Failures and Future Hopes Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics Cardioprotective functions of HDLs Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules High-Density Lipoprotein Processing and Premature Cardiovascular Disease Evaluating and treating cardiometabolic risk factors: a case discussion Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk Therapy insight: heart disease and the insulin-resistant patient.The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Nuclear receptors as drug targets for metabolic disease.Screening the human serum proteome for genotype-phenotype associations: an analysis of the IL6 -174G>C polymorphism.Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Study of Cholesteryl Ester Transfer Protein (CETP) I405v Genotype and Its Association with Lipid Fractions in Myocardial Infarction Patients: A Case Control Study.Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation.Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patients Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2)Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies CETP genotype and changes in lipid levels in response to weight-loss diet intervention in the POUNDS LOST and DIRECT randomized trials.eNOS activation by HDL is impaired in genetic CETP deficiency.Molecular regulation of HDL metabolism and function: implications for novel therapies.New insights into the mechanism of low high-density lipoprotein cholesterol in obesity Pathophysiology of dyslipidaemia in the metabolic syndrome.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Endothelial FAK as a therapeutic target in disease.

P2860

Q24323992-E6677160-331A-468F-B856-D05497C9CB09 Q24624286-46D82C13-C924-42ED-A48F-A467CDFCDF7F Q24650533-1664D7CE-E0A4-4C1D-8C50-2C8E60D4D40C Q24802369-D014A185-A305-4EBB-B953-58B756C14580 Q26753158-58E04E02-31A4-40CE-839C-63CDC6CC8577 Q26774903-F1C6D691-A82B-4F29-AAF1-ADBF795A0C3C Q27000421-68B444B3-647E-4EA5-AB2E-0D7EE204D69B Q27643587-96A5F68A-C6BA-43AA-A73C-982732B9AB9E Q28085143-2104CE4F-AFD2-4831-95E7-02FB9E2BC37C Q28196750-11964969-80DF-48CB-B34B-8B4DD22E5CC3 Q28200554-F37FFA5F-593B-4FB0-AB21-7CF8169BA41D Q28285064-29480800-D7D9-484D-8903-89384FFF06AB Q28570515-24F6569B-5248-4D48-BA7A-7A53BB184B69 Q28594013-C574A815-2387-4278-870E-FBC8326A09ED Q28731522-8AB3288F-AE43-48A4-A693-969CB40CA8FF Q30351748-FD489B81-3B37-4C5A-B1E5-AF86914FA7EF Q30380628-B17034D1-2BE2-43FC-9304-5DA692FAF84E Q30430126-7D7D2440-8AB0-4943-B701-205AF26AF167 Q33274516-1263986E-6A4F-46B2-8B63-A4A47019FCA5 Q33612543-D45E53A2-73DB-4D3A-9C95-3C0EBDB71C33 Q33639433-49A8C403-B9A8-42AB-8C92-02B8421C431B Q33717612-43E82147-335A-4F3D-9E2E-7A2515E01774 Q33924365-909705A4-BBD3-4051-968D-4E3AE853E78F Q33993233-DD36E3B5-D19F-4471-9C42-D21230406293 Q34030331-9724D52E-DDF6-4898-85E3-8E2CC52B1889 Q34075414-A608D91B-8157-4BDA-B4CE-BD9E8996F148 Q34236254-2E82D730-F5E7-4D57-A2BC-3136C8A75851 Q34238630-FA608AFD-345B-439C-B978-9F03499A009E Q34243501-82DED5A7-BDD2-4D45-9DDF-80D004B52E4C Q34441411-D8BE59D9-634C-40B8-A842-3C68C53016F2 Q34578466-DEB0EE13-A7A1-4759-BB44-9B30A773A1B7 Q34628218-9C3D26BF-6BB3-43D9-94DF-8857D7850D56 Q35032753-DE430590-9FDE-42CE-9713-6A20531510B9 Q35120965-A4000090-36FD-4285-983D-A2A391F7B799 Q35168995-ADBFB643-4B74-4FA8-84B8-D284CCB03543 Q35191066-8CDE4206-0032-40C9-B294-CB3FD38E4A18 Q35521069-4834F6B0-30C0-493C-9D3E-5F6115E98EDE Q35522107-DCE937F8-E570-4ABC-B4B8-23CE953AF885 Q35590298-E3408EB6-274B-4309-9FE3-EADAABE0A0AB Q35597214-DA22733A-0AC1-4876-A121-66A4BE7D1B10

P2860

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

http://www.wikidata.org/entity/Q28255410

description

2004 nî lūn-bûn

@nan

2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@ast

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@en

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@nl

type

label

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@ast

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@en

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@nl

prefLabel

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@ast

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@en

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@nl

P1433

Q28255410-98B12A04-977A-4CE5-AD94-ED93608752BD

P1476

Q28255410-9619CFD6-584E-4C35-B250-DCDC92148ECC

P2093

Q28255410-092193CA-D669-4018-839F-3FA38A40372B

Q28255410-1652CB1C-D570-4FA6-8A16-1E8358915CEC

Q28255410-1D967975-F931-4F1A-9EFF-0C0A733D0C70

Q28255410-2EDB399A-D3AF-4AE1-A518-4EE093889F88

Q28255410-39FCC063-67FB-4418-8B4D-B1204D5FD316

Q28255410-516C490C-5AA5-4B8A-85FD-E868D0D0C525

Q28255410-B88BCE25-222D-4CBE-81D6-52F29ADF156A

Q28255410-CF560054-9322-4B79-84E4-45581E31A0CF

P304

Q28255410-3EE88B89-81D0-4C35-B40D-04BD8B5B8F18

P31

Q28255410-6828B958-603C-4502-BEE6-B2CCCD733E73

P3181

Q28255410-8AE9B86E-1277-4926-A1BB-55C42EDCFF03

P356

Q28255410-231F1EBB-E56B-4D92-99E6-16D9B98BAFC8

P407

Q28255410-01458C32-6CCC-431A-9395-DF0C9B0F220C

P433

Q28255410-FA0AF81C-DC74-46E1-9DD2-EDB2D76ED816

P478

Q28255410-E936771D-EA03-4A6F-8962-2E6C45C5DF4A

P577

Q28255410-E88763A7-8606-43E4-892A-C491C89B2F5B

P698

Q28255410-D25E7F21-8459-4721-935C-68911760B739

P3181

P356

P1433

The New England Journal of Medicine

P1476

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

@en

P2093

Andres G Digenio

http://www.w3.org/2001/XMLSchema#string

Daniel J Rader

http://www.w3.org/2001/XMLSchema#string

Ernst J Schaefer

http://www.w3.org/2001/XMLSchema#string

James P Mancuso

http://www.w3.org/2001/XMLSchema#string

LeAnne T Bloedon

http://www.w3.org/2001/XMLSchema#string

Margaret E Brousseau

http://www.w3.org/2001/XMLSchema#string

Megan L Wolfe

http://www.w3.org/2001/XMLSchema#string

Ronald W Clark

http://www.w3.org/2001/XMLSchema#string

P304

1505-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4749625

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA031766

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P577

2004-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15071125

http://www.w3.org/2001/XMLSchema#string